首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1544543

銅綠假單胞菌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Pseudomonas Aeruginosa Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月01日 | 出版商:

Global Market Insights Inc. | 英文 225 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年至2032年，全球銅綠假單胞菌治療市場的複合年成長率將達到5.8%，這主要是由院內感染發生率上升和慢性病盛行率上升所推動的。銅綠假單胞菌因其對許多傳統抗生素具有抗藥性而聞名，它對醫療保健環境構成了重大挑戰，特別是對於免疫系統受損的患者。醫學研發的進步導致針對銅綠假單胞菌抗藥性菌株的新型抗菌藥物和療法的推出。例如，2023 年 7 月，Flagship Pioneering 和輝瑞宣佈建立 1 億美元的合作關係，開發 10 種創新藥物，以滿足未滿足的需求。此次合作將透過 Flagship 的生態系統和輝瑞的研發探索新療法，潛在的里程碑和特許權使用費高達 7 億美元。

此外，個人化醫療和標靶藥物輸送系統的興起使疾病管理變得越來越可行。人們越來越認知到有效的感染控制措施和擴大醫療基礎設施的重要性，這將有助於市場的擴張。

銅綠假單胞菌治療市場根據治療、藥物類型、感染類型、類型、給藥途徑、配銷通路和區域進行分類。

到 2032 年，單一療法領域的複合年成長率將引人注目，這歸因於單藥療法對細菌抗藥性菌株的療效。與聯合療法相比，單一療法提供了一種有針對性的方法，簡化了治療方案並最大限度地減少了潛在的藥物交互作用。藥物開發的進步催生了有效對抗銅綠假單胞菌的有效單一療法選擇。這種方法提高了患者的依從性並降低了抗藥性產生的風險，從而促使人們越來越傾向於單一療法。

到 2032 年，頭孢菌素藥物類型部分將佔據相當大的市場佔有率，因為它們具有廣譜活性和對一系列細菌感染的有效性。隨著新一代頭孢菌素的開發，其效力增強，藥物動力學改善，它們提供了有針對性的治療解決方案。頭孢菌素類藥物在臨床上的成功以及在醫院環境和門診護理中越來越多的採用正在促進該細分市場的佔有率。

歐洲銅綠假單胞菌治療市場將在2024年至2032年間呈現顯著的複合年成長率。有效治療的需求。歐洲強大的醫療保健基礎設施和對醫療研發的大量投資有助於提供先進的治療選擇。嚴格的感染控制措施和對抗生素管理計劃的認知不斷提高，透過促進採用有針對性的有效療法進一步支持市場成長。

產業生態系統分析
產業影響力
- 成長動力
  - 假單胞菌感染發生率上升
  - 診斷技術的進步
  - 持續的研發活動專注於創造新的抗生素
- 產業陷阱與挑戰
  - 抗生素抗藥性上升
  - 潛在的嚴重副作用和不良反應
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按處理方式，2021 - 2032

主要趨勢
單一療法
合併治療

第 6 章：市場估計與預測：按藥物類型，2021 - 2032 年

主要趨勢
氨基糖苷類
頭孢菌素類
碳青黴烯類
單菌醯胺類
其他藥物類型

第 7 章：市場估計與預測：按感染類型，2021 - 2032 年

主要趨勢
呼吸道感染
泌尿道感染（UTI）
血流感染
皮膚和軟組織感染
眼睛和耳朵感染
其他類型的感染

第 8 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
品牌化
泛型

第 9 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
口服
注射用
其他給藥途徑

第 10 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 11 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 12 章：公司簡介

AbbVie Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
Baxter International Inc.
Lupin Pharmaceuticals Inc.
Merck and Co. Inc.
Neopharma
Novartis AG
Pfizer Inc.
Sanofi SA
Shionogi and Co., Ltd.
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 10073

Global Pseudomonas Aeruginosa Treatment Market will witness a 5.8% CAGR from 2024 to 2032, primarily driven by the rising incidence of hospital-acquired infections and the prevalence of chronic diseases. Known for its resistance to many conventional antibiotics, pseudomonas aeruginosa poses a significant challenge in healthcare settings, particularly among patients with compromised immune systems. Advancements in medical R and D have led to the introduction of novel antimicrobial agents and therapies targeting resistant strains of pseudomonas aeruginosa. For instance, in July 2023, Flagship Pioneering and Pfizer announced a $100Mn partnership to develop 10 innovative medicines targeting unmet needs. The collaboration will explore new therapies through Flagship's ecosystem and Pfizer's R and D, with potential milestones and royalties up to $700Mn.

Further, the rise of personalized medicine and targeted drug delivery systems is making disease management increasingly feasible. The growing awareness about the importance of effective infection control measures and the expansion of healthcare infrastructure will contribute to the market expansion.

The pseudomonas aeruginosa treatment market is classified based on treatment, drug type, type of infection, type, route of administration, distribution channel, and region.

The monotherapy segment will register a noteworthy CAGR through 2032, attributable to the efficacy of single-agent therapies against resistant strains of the bacteria. Monotherapy offers a targeted approach, simplifying treatment regimens and minimizing potential drug interactions compared to combination therapies. Advances in drug development have led to the creation of potent monotherapy options that effectively combat pseudomonas aeruginosa. This approach improves patient compliance and reduces the risk of resistance development, contributing to the growing preference for monotherapy.

The cephalosporins drug type segment will grab a considerable market share by 2032, due to their broad-spectrum activity and effectiveness against an array of bacterial infections. As newer generations of cephalosporins are developed with enhanced potency and improved pharmacokinetics, they provide targeted therapeutic solutions. The clinical success and increasing adoption of cephalosporins in hospital settings and outpatient care is contributing to the segment share.

Europe pseudomonas aeruginosa treatment market will exhibit a significant CAGR between 2024 and 2032. The increased prevalence of hospital-acquired infections and chronic diseases, which elevate the risk of pseudomonas aeruginosa infections, ushers demand for effective treatments. Europe's robust healthcare infrastructure and significant investment in medical R and D contribute to the availability of advanced therapeutic options. The strict infection control practices and rising awareness of antibiotic stewardship programs further support market growth by promoting the adoption of targeted and effective therapies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of pseudomonas infections
  - 3.2.1.2 Advancements in diagnostic technologies
  - 3.2.1.3 Ongoing research and development activities focused on creating new antibiotics
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Rise in antibiotic resistance
  - 3.2.2.2 Potential for severe side effects and adverse reaction
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Monotherapy
5.3 Combination therapy

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Aminoglycosides
6.3 Cephalosporins
6.4 Carbapenems
6.5 Monobactams
6.6 Other drug types

Chapter 7 Market Estimates and Forecast, By Type of Infection, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Respiratory tract infections
7.3 Urinary tract infections (UTIs)
7.4 Bloodstream infections
7.5 Skin and soft tissue infections
7.6 Eye and ear infections
7.7 Other types of infections

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Branded
8.3 Generics

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Oral
9.3 Parenteral
9.4 Other routes of administration

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Poland
- 11.3.7 Netherlands
- 11.3.8 Rest of Europe
11.4 Asia Pacific
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 UAE
- 11.6.4 Rest of Middle East and Africa